- Treatment of infections due to susceptible organisms including Bordetella pertussis and Chlamydia trachomatis
- IV intermittent infusion: over 1 hour
- Intravenous administration should only be considered when oral therapy not suitable
- PO
IV/PO
- 10 mg/kg/dose once daily for 5 days
- CVS: ventricular arrhythmia, prolongation of QTc interval, bradycardia
- GI: diarrhea, vomiting, infantile hypertrophic stenosis (extremely rare)
- Hematologic: anemia, leukopenia, thrombocytopenia
- Hepatic: cholestatic hepatitis, jaundice, LFT's increased
- Local: venous irritation, inflammation (with IV administration)
- Renal: interstitial nephritis
- Liver function tests
- WBC with differential
- Injection site
- Azithromycin 500 mg vial
- Add 4.8 mL of SWFI
- Take 1 mL (100 mg) and add to 49 mL D5W
- Final concentration: 2 mg/mL*
* Infusion of Azithromycin with a concentration greater than 2 mg/mL will result in a local infusion site reaction and should be avoided.
- Solutions Compatible: D5W, 0.45%NaCl, 0.9%NaCl, D5W/0.45%NaCl, D5W/0.9%NaCl
- Y-site Compatible (when azithromycin is diluted in D5W): calcium gluconate, cefotaxime (up to 20 mg/mL), dobutamine, dopamine, epinephrine (up to 50 mcg/mL), fentanyl, gentamicin, heparin, morphine, potassium chloride, tobramycin
Incompatible: midazolam
- Oral bioavailability of the oral suspension is increased by feeds
- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc;2015
- Pickering LK, ed 2012 Red Book: Report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2012
- American Society of Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 19th Edition, Bethesda: ASHP 2017